Activities of Eravacycline, Tedizolid, Norvancomycin, Nemonoxacin, Ceftaroline, and Comparators against 1,871 Staphylococcus and 1,068 Enterococcus Species Isolates from China: Updated Report of the CHINET Study 2019
ABSTRACT To evaluate the in vitro activities of eravacycline, tedizolid, nemonoxacin, norvancomycin, and ceftaroline against Staphylococcus and Enterococcus species isolates were collected as part of the China Antimicrobial Surveillance Network (CHINET) in 2019 to provide susceptibility data for Sta...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
American Society for Microbiology
2022-12-01
|
| Series: | Microbiology Spectrum |
| Subjects: | |
| Online Access: | https://journals.asm.org/doi/10.1128/spectrum.01715-22 |
| _version_ | 1798003836655239168 |
|---|---|
| author | Li Ding Yang Yang Changhe Zheng Gang Sun Renru Han Yan Guo Dandan Yin Shi Wu Demei Zhu Fupin Hu |
| author_facet | Li Ding Yang Yang Changhe Zheng Gang Sun Renru Han Yan Guo Dandan Yin Shi Wu Demei Zhu Fupin Hu |
| author_sort | Li Ding |
| collection | DOAJ |
| description | ABSTRACT To evaluate the in vitro activities of eravacycline, tedizolid, nemonoxacin, norvancomycin, and ceftaroline against Staphylococcus and Enterococcus species isolates were collected as part of the China Antimicrobial Surveillance Network (CHINET) in 2019 to provide susceptibility data for Staphylococcus spp. and Enterococcus spp. for their future development and application in clinical practice. Antimicrobial susceptibility testing was performed using the CLSI broth microdilution reference method. Eravacycline was highly active against Staphylococcus and Enterococcus species isolates, proved by the MIC50/90: 0.06/0.125, 0.06/0.25, 0.06/0.25, 0.06/0.25, 0.125/0.5, 0.125/0.25, and 0.03/0.06 mg/L for Staphylococcus aureus, methicillin-resistant S. aureus (MRSA), S. epidermidis, S. hominis, S. haemolyticus, Enterococcus faecalis, and E. faecium, respectively. S. aureus isolates tested were fully susceptible to tedizolid. Still, nonsusceptible isolates were found for E. faecalis (72/567 [12.7%]) and E. faecium (12/501 [2.4%]). Norvancomycin at 2 mg/L could inhibit 100% of Staphylococcus spp., while 1 mg/L of ceftaroline could inhibit 78.9% of MRSA and 99.9% of methicillin-susceptible S. aureus (MSSA) isolates. Additionally, nemonoxacin was also active against Staphylococcus and Enterococcus species isolates tested (shown by the following MIC90s and ranges, in milligrams per liter: 2 and ≤0.015 to 8 for MRSA, 0.25 and ≤0.015 to 4 for MSSA, 0.5 and ≤0.015 to 8 for S. epidermidis, and 4 and ≤0.015 to >32 for E. faecalis). In conclusion, both eravacycline and tedizolid were highly active against clinical isolates of Staphylococcus spp. and Enterococcus spp. recently collected across China. Nemonoxacin showed potent activity against Staphylococcus spp. and E. faecalis but limited activity against E. faecium. Norvancomycin and ceftaroline displayed highly potent activity against Staphylococcus spp. IMPORTANCE Antimicrobial resistance has become a severe threat to global public health. According to statistics, nearly 700,000 people die from bacterial infections worldwide (J. O’Neill, Antimicrobial Resistance: Tackling a Crisis for the Health and Wealth of Nations, 2014; C. Y. Chin, K. A. Tipton, M. Farokhyfar, E. M. Burd, et al., Nat Microbiol 3:563–569, 2018, https://doi.org/10.1038/s41564-018-0151-5). The number of bacterial infections is expected to climb to 10 million by 2050, showing that bacterial resistance has become a significant problem that cannot be ignored. It is crucial to develop new antimicrobial agents to combat antimicrobial-resistant bacteria. In this study, we evaluated the in vitro activities of eravacycline, tedizolid, nemonoxacin, norvancomycin, and ceftaroline against Staphylococcus spp. and Enterococcus species isolates which were collected as part of CHINET in 2019. We believe that this study can provide susceptibility data for Staphylococcus spp. and Enterococcus spp. for their future development and application in clinical practice. |
| first_indexed | 2024-04-11T12:13:59Z |
| format | Article |
| id | doaj.art-83e025bc2d074f08bcb076dc53d6f33d |
| institution | Directory Open Access Journal |
| issn | 2165-0497 |
| language | English |
| last_indexed | 2024-04-11T12:13:59Z |
| publishDate | 2022-12-01 |
| publisher | American Society for Microbiology |
| record_format | Article |
| series | Microbiology Spectrum |
| spelling | doaj.art-83e025bc2d074f08bcb076dc53d6f33d2022-12-22T04:24:25ZengAmerican Society for MicrobiologyMicrobiology Spectrum2165-04972022-12-0110610.1128/spectrum.01715-22Activities of Eravacycline, Tedizolid, Norvancomycin, Nemonoxacin, Ceftaroline, and Comparators against 1,871 Staphylococcus and 1,068 Enterococcus Species Isolates from China: Updated Report of the CHINET Study 2019Li Ding0Yang Yang1Changhe Zheng2Gang Sun3Renru Han4Yan Guo5Dandan Yin6Shi Wu7Demei Zhu8Fupin Hu9Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, ChinaInstitute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, ChinaYancheng Tinghu District People’s Hospital, Jiangsu, ChinaThe First Division Hospital of Xinjiang Corps, Xinjiang, ChinaInstitute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, ChinaInstitute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, ChinaInstitute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, ChinaInstitute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, ChinaInstitute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, ChinaInstitute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, ChinaABSTRACT To evaluate the in vitro activities of eravacycline, tedizolid, nemonoxacin, norvancomycin, and ceftaroline against Staphylococcus and Enterococcus species isolates were collected as part of the China Antimicrobial Surveillance Network (CHINET) in 2019 to provide susceptibility data for Staphylococcus spp. and Enterococcus spp. for their future development and application in clinical practice. Antimicrobial susceptibility testing was performed using the CLSI broth microdilution reference method. Eravacycline was highly active against Staphylococcus and Enterococcus species isolates, proved by the MIC50/90: 0.06/0.125, 0.06/0.25, 0.06/0.25, 0.06/0.25, 0.125/0.5, 0.125/0.25, and 0.03/0.06 mg/L for Staphylococcus aureus, methicillin-resistant S. aureus (MRSA), S. epidermidis, S. hominis, S. haemolyticus, Enterococcus faecalis, and E. faecium, respectively. S. aureus isolates tested were fully susceptible to tedizolid. Still, nonsusceptible isolates were found for E. faecalis (72/567 [12.7%]) and E. faecium (12/501 [2.4%]). Norvancomycin at 2 mg/L could inhibit 100% of Staphylococcus spp., while 1 mg/L of ceftaroline could inhibit 78.9% of MRSA and 99.9% of methicillin-susceptible S. aureus (MSSA) isolates. Additionally, nemonoxacin was also active against Staphylococcus and Enterococcus species isolates tested (shown by the following MIC90s and ranges, in milligrams per liter: 2 and ≤0.015 to 8 for MRSA, 0.25 and ≤0.015 to 4 for MSSA, 0.5 and ≤0.015 to 8 for S. epidermidis, and 4 and ≤0.015 to >32 for E. faecalis). In conclusion, both eravacycline and tedizolid were highly active against clinical isolates of Staphylococcus spp. and Enterococcus spp. recently collected across China. Nemonoxacin showed potent activity against Staphylococcus spp. and E. faecalis but limited activity against E. faecium. Norvancomycin and ceftaroline displayed highly potent activity against Staphylococcus spp. IMPORTANCE Antimicrobial resistance has become a severe threat to global public health. According to statistics, nearly 700,000 people die from bacterial infections worldwide (J. O’Neill, Antimicrobial Resistance: Tackling a Crisis for the Health and Wealth of Nations, 2014; C. Y. Chin, K. A. Tipton, M. Farokhyfar, E. M. Burd, et al., Nat Microbiol 3:563–569, 2018, https://doi.org/10.1038/s41564-018-0151-5). The number of bacterial infections is expected to climb to 10 million by 2050, showing that bacterial resistance has become a significant problem that cannot be ignored. It is crucial to develop new antimicrobial agents to combat antimicrobial-resistant bacteria. In this study, we evaluated the in vitro activities of eravacycline, tedizolid, nemonoxacin, norvancomycin, and ceftaroline against Staphylococcus spp. and Enterococcus species isolates which were collected as part of CHINET in 2019. We believe that this study can provide susceptibility data for Staphylococcus spp. and Enterococcus spp. for their future development and application in clinical practice.https://journals.asm.org/doi/10.1128/spectrum.01715-22Staphylococcus spp.Enterococcus spp.eravacyclinetedizolidnemonoxacinnorvancomycin |
| spellingShingle | Li Ding Yang Yang Changhe Zheng Gang Sun Renru Han Yan Guo Dandan Yin Shi Wu Demei Zhu Fupin Hu Activities of Eravacycline, Tedizolid, Norvancomycin, Nemonoxacin, Ceftaroline, and Comparators against 1,871 Staphylococcus and 1,068 Enterococcus Species Isolates from China: Updated Report of the CHINET Study 2019 Microbiology Spectrum Staphylococcus spp. Enterococcus spp. eravacycline tedizolid nemonoxacin norvancomycin |
| title | Activities of Eravacycline, Tedizolid, Norvancomycin, Nemonoxacin, Ceftaroline, and Comparators against 1,871 Staphylococcus and 1,068 Enterococcus Species Isolates from China: Updated Report of the CHINET Study 2019 |
| title_full | Activities of Eravacycline, Tedizolid, Norvancomycin, Nemonoxacin, Ceftaroline, and Comparators against 1,871 Staphylococcus and 1,068 Enterococcus Species Isolates from China: Updated Report of the CHINET Study 2019 |
| title_fullStr | Activities of Eravacycline, Tedizolid, Norvancomycin, Nemonoxacin, Ceftaroline, and Comparators against 1,871 Staphylococcus and 1,068 Enterococcus Species Isolates from China: Updated Report of the CHINET Study 2019 |
| title_full_unstemmed | Activities of Eravacycline, Tedizolid, Norvancomycin, Nemonoxacin, Ceftaroline, and Comparators against 1,871 Staphylococcus and 1,068 Enterococcus Species Isolates from China: Updated Report of the CHINET Study 2019 |
| title_short | Activities of Eravacycline, Tedizolid, Norvancomycin, Nemonoxacin, Ceftaroline, and Comparators against 1,871 Staphylococcus and 1,068 Enterococcus Species Isolates from China: Updated Report of the CHINET Study 2019 |
| title_sort | activities of eravacycline tedizolid norvancomycin nemonoxacin ceftaroline and comparators against 1 871 staphylococcus and 1 068 enterococcus species isolates from china updated report of the chinet study 2019 |
| topic | Staphylococcus spp. Enterococcus spp. eravacycline tedizolid nemonoxacin norvancomycin |
| url | https://journals.asm.org/doi/10.1128/spectrum.01715-22 |
| work_keys_str_mv | AT liding activitiesoferavacyclinetedizolidnorvancomycinnemonoxacinceftarolineandcomparatorsagainst1871staphylococcusand1068enterococcusspeciesisolatesfromchinaupdatedreportofthechinetstudy2019 AT yangyang activitiesoferavacyclinetedizolidnorvancomycinnemonoxacinceftarolineandcomparatorsagainst1871staphylococcusand1068enterococcusspeciesisolatesfromchinaupdatedreportofthechinetstudy2019 AT changhezheng activitiesoferavacyclinetedizolidnorvancomycinnemonoxacinceftarolineandcomparatorsagainst1871staphylococcusand1068enterococcusspeciesisolatesfromchinaupdatedreportofthechinetstudy2019 AT gangsun activitiesoferavacyclinetedizolidnorvancomycinnemonoxacinceftarolineandcomparatorsagainst1871staphylococcusand1068enterococcusspeciesisolatesfromchinaupdatedreportofthechinetstudy2019 AT renruhan activitiesoferavacyclinetedizolidnorvancomycinnemonoxacinceftarolineandcomparatorsagainst1871staphylococcusand1068enterococcusspeciesisolatesfromchinaupdatedreportofthechinetstudy2019 AT yanguo activitiesoferavacyclinetedizolidnorvancomycinnemonoxacinceftarolineandcomparatorsagainst1871staphylococcusand1068enterococcusspeciesisolatesfromchinaupdatedreportofthechinetstudy2019 AT dandanyin activitiesoferavacyclinetedizolidnorvancomycinnemonoxacinceftarolineandcomparatorsagainst1871staphylococcusand1068enterococcusspeciesisolatesfromchinaupdatedreportofthechinetstudy2019 AT shiwu activitiesoferavacyclinetedizolidnorvancomycinnemonoxacinceftarolineandcomparatorsagainst1871staphylococcusand1068enterococcusspeciesisolatesfromchinaupdatedreportofthechinetstudy2019 AT demeizhu activitiesoferavacyclinetedizolidnorvancomycinnemonoxacinceftarolineandcomparatorsagainst1871staphylococcusand1068enterococcusspeciesisolatesfromchinaupdatedreportofthechinetstudy2019 AT fupinhu activitiesoferavacyclinetedizolidnorvancomycinnemonoxacinceftarolineandcomparatorsagainst1871staphylococcusand1068enterococcusspeciesisolatesfromchinaupdatedreportofthechinetstudy2019 |